Table 2.
Compound/concentrationa (μg/kg lipids) | n (cases/subcohort) | IRR (95% CI) | ||||
---|---|---|---|---|---|---|
Model 1b | Model 2c | |||||
p,p´-DDT | ||||||
6–15 | 29/37 | 1.00 | 1.00 | |||
15–22 | 32/32 | 1.09 (0.54, 2.18) | 1.06 (0.52, 2.14) | |||
22–36 | 35/38 | 1.12 (0.57, 2.19) | 1.03 (0.51, 2.09) | |||
36–49 | 23/19 | 1.25 (0.55, 2.80) | 1.21 (0.53, 2.75) | |||
49–460 | 18/11 | 1.73 (0.72, 4.14) | 1.64 (0.68, 3.96) | |||
Linear estimate per IQRd | 137/137 | 1.36 (1.11, 1.68) | 1.35 (1.10, 1.66) | |||
p,p´-DDE | ||||||
68–390 | 59/58 | 1.00 | 1.00 | |||
390–680 | 53/64 | 0.82 (0.49, 1.37) | 0.83 (0.49, 1.39) | |||
680–1,100 | 63/57 | 1.03 (0.62, 1.72) | 1.04 (0.62, 1.73) | |||
1,100–1,700 | 34/36 | 0.82 (0.45, 1.50) | 0.79 (0.43, 1.46) | |||
1,700–8,000 | 29/22 | 1.12 (0.58, 2.17) | 1.10 (0.57, 2.14) | |||
Linear estimate per IQRd | 238/237 | 1.03 (0.86, 1.22) | 1.02 (0.86, 1.22) | |||
β-Hexachlorocyclohexane | ||||||
15–45 | 50/60 | 1.00 | 1.00 | |||
45–57 | 50/54 | 1.15 (0.67, 1.99) | 1.15 (0.66, 2.00) | |||
57–77 | 61/58 | 1.27 (0.74, 2.17) | 1.24 (0.72, 2.15) | |||
77–96 | 38/25 | 1.59 (0.83, 3.03) | 1.49 (0.76, 2.92) | |||
96–370 | 26/23 | 1.06 (0.53, 2.11) | 1.02 (0.50, 2.07) | |||
Linear estimate per IQRd | 225/220 | 0.99 (0.83, 1.17) | 0.96 (0.81, 1.15) | |||
cis-Nonachlor | ||||||
3–5 | 30/50 | 1.00 | 1.00 | |||
5–7 | 35/42 | 1.23 (0.64, 2.35) | 1.19 (0.61, 2.30) | |||
7–10 | 42/32 | 1.56 (0.82, 2.96) | 1.53 (0.80, 2.91) | |||
10–15 | 27/21 | 1.64 (0.79, 3.41) | 1.76 (0.84, 3.67) | |||
15–39 | 21/11 | 2.60 (1.08, 6.27) | 2.52 (1.04, 6.09) | |||
Linear estimate per IQRd | 155/156 | 1.13 (0.94, 1.36) | 1.13 (0.94, 1.36) | |||
trans-Nonachlor | ||||||
6–25 | 47/67 | 1.00 | 1.00 | |||
25–33 | 53/52 | 1.33 (0.78, 2.28) | 1.39 (0.81, 2.39) | |||
33–46 | 65/60 | 1.40 (0.84, 2.36) | 1.43 (0.85, 2.40) | |||
46–62 | 41/33 | 1.37 (0.75, 2.52) | 1.38 (0.75, 2.54) | |||
62–290 | 29/20 | 1.60 (0.79, 3.24) | 1.54 (0.76, 3.14) | |||
Linear estimate per IQRd | 235/232 | 1.03 (0.90, 1.18) | 1.01 (0.89, 1.16) | |||
Compound/concentrationa (μg/kg lipids) | n (cases/subcohort) | IRR (95% CI) | ||||
Model 1b | Model 2c | |||||
Oxychlordane | ||||||
8–19 | 30/52 | 1.00 | 1.00 | |||
19–25 | 38/46 | 1.31 (0.71, 2.43) | 1.33 (0.72, 2.46) | |||
25–33 | 46/39 | 1.87 (1.00, 3.49) | 1.86 (1.00, 3.47) | |||
33–41 | 34/18 | 2.81 (1.28, 6.14) | 2.69 (1.22, 5.96) | |||
41–354 | 21/16 | 1.95 (0.85, 4.46) | 1.92 (0.84, 4.41) | |||
Linear estimate per IQRd | 169/171 | 1.13 (0.92, 1.40) | 1.11 (0.89, 1.38) | |||
Dieldrin | ||||||
6–13 | 33/32 | 1.00 | 1.00 | |||
13–20 | 21/52 | 0.38 (0.19, 0.76) | 0.36 (0.17, 0.73) | |||
20–29 | 35/37 | 0.95 (0.49, 1.85) | 0.91 (0.46, 1.79) | |||
29–41 | 22/12 | 2.05 (0.92, 4.54) | 1.94 (0.87, 4.34) | |||
41–350 | 18/11 | 1.42 (0.60, 3.36) | 1.27 (0.52, 3.12) | |||
Linear estimate per IQRd | 140/144 | 1.03 (0.94, 1.14) | 1.03 (0.94, 1.13) | |||
Hexachlorobenzene | ||||||
9–37 | 47/56 | 1.00 | 1.00 | |||
37–53 | 50/51 | 1.08 (0.62, 1.88) | 1.07 (0.61, 1.87) | |||
53–72 | 45/56 | 0.84 (0.48, 1.49) | 0.77 (0.42, 1.43) | |||
72–98 | 37/33 | 1.15 (0.60, 2.18) | 1.07 (0.55, 2.09) | |||
98–360 | 25/17 | 1.25 (0.57, 2.72) | 1.16 (0.53, 2.58) | |||
Linear estimate per IQRd | 204/213 | 1.00 (0.82, 1.21) | 0.98 (0.80, 1.19) | |||
ΣChlordanese | ||||||
9–37 | 55/59 | 1.00 | 1.00 | |||
37–58 | 51/68 | 0.77 (0.46, 1.30) | 0.75 (0.44, 1.27) | |||
58–83 | 64/53 | 1.18 (0.70, 1.99) | 1.10 (0.64, 1.91) | |||
83–108 | 35/35 | 0.84 (0.45, 1.55) | 0.80 (0.43, 1.50) | |||
108–439 | 30/17 | 1.41 (0.68, 2.94) | 1.32 (0.63, 2.79) | |||
Linear estimate per IQRf | 235/232 | 1.04 (0.86, 1.26) | 1.02 (0.84, 1.24) | |||
ΣDDTsg | ||||||
76–390 | 57/56 | 1.00 | 1.00 | |||
390–690 | 57/67 | 0.86 (0.51, 1.43) | 0.87 (0.52, 1.47) | |||
690–1,100 | 61/56 | 1.02 (0.61, 1.72) | 1.03 (0.61, 1.74) | |||
1,100–1,714 | 36/37 | 0.86 (0.48, 1.56) | 0.83 (0.46, 1.52) | |||
1,714–8,041 | 27/21 | 1.09 (0.56, 2.15) | 1.08 (0.55, 2.14) | |||
Linear estimate per IQRh | 238/237 | 1.03 (0.87, 1.23) | 1.03 (0.86, 1.23) |